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INTRODUCTION
The blood loss accompanying orthopedic
surgery can be significant, anemia of total
hip arthroplasty being a frequent compli-
cation. Surgeons have developed different
techniques for hip arthroplasty in an effort
to reduce morbidity from risks such as
infection, blood loss, mobility impairment,
and impaired wound healing.
Since the first hip arthroplasty of the
modern era was performed, Dr. Charnley’s
“low-friction arthroplasty” creating the
bases of two-component modern design,
various surgical techniques were typically
chosen according to surgeons’ personal
preferences and local traditions (1). Com-
parisons of two common techniques, DAA
and PA, did not report any conclusive data
regarding the superiority of one method
to the other (2–8). Among the risks of
hip arthroplasty, the need for blood trans-
fusion is a significant one. For the pur-
pose of this review, database searches were
performed using the keywords total hip
arthroplasty, blood loss, transfusion, poste-
rior approach,and direct anterior approach
indicated blood transfusion as an indepen-
dent risk factor for increased length of hos-
pital stay (LOS), post-operative infections,
and post-operative mobility impairment
(2, 9, 10).
The newer DAA techniques are pro-
moted as muscle-sparing and as requir-
ing shorter recovery times (3). Although
greater trochanteric intra-operative frac-
ture and lateral femoral cutaneous nerve
(LFCN) neuropraxia were more com-
mon with the DAA, all patients ulti-
mately recovered without complications
(2). Recent publications report several dis-
advantages associated with the DAA, the
most significant being the cost of a spe-
cial table (approximately $100,000) (4),
the need for intra-operative fluoroscopy
linked to an extended procedure length
and draping contamination, LFCN injury,
and bleeding from the circumflex vessels
(4, 5).
An extensive retrospective analysis pub-
lished by Christensen et al. in 2014
reviewed anterior and posterior THA pro-
cedures performed by a single board-
certified orthopedic surgeon between 2003
and 2014. Data collected from 1,793
patients supported previous reports of
increased re-intervention rates linked to
the DAA (6).
Blood-management techniques in
orthopedic surgeries are a ubiquitous sub-
ject within the medical literature. However,
there is little consensus between anes-
thesiologists and surgeons on acceptable
guidelines and practices (11). Commonly,
efforts are made by primary care physicians
(PCP), anesthesiologists, and surgeons
to detect and treat anemia in patients
undergoing elective orthopedic surgeries.
Multiple national surveys of blood dona-
tions and transfusions within the US,
found an increase of 4–5% in allogeneic
blood units transfused within the last
15 years (12). Increased awareness of the
disadvantages linked to allogeneic blood
transfusion (ABT) following orthopedic
surgeries has triggered an effort to min-
imizing its use. A review published by
Lemaire in 2008 advised orthopedic sur-
geons, when performing elective surgeries,
to take into consideration the preoperative
erythrocyte stock, the anticipated periop-
erative blood loss, and the acceptable blood
loss for a specific patient (13). Based on
these reports, increased attention has been
placed on the short-term perioperative
outcome associated with different tech-
niques used in THA. Martin et al. found
that patients who underwent a DAA tech-
nique had a shorter LOS and experienced
earlier mobilization compared to patients
who received the PA. ABT was mentioned
as a predictor of mobility failure following
THA (2). A similar result was reported by
Schweppe et al. while analyzing hospital-
related outcomes of the DAA versus the
PA in 200 patients (100 per each arm)
(14). Recent prospective studies supported
previous reports that the DAA results in
a decreased LOS despite a longer surgi-
cal time with significantly more blood
loss (15).
A review and meta-analysis of clinical
outcomes including blood loss following
total hip arthroplasty performed via the
anterior versus posterior approach found
no superiority of either method. A lower
blood loss associated with the posterior
approach was not considered statistically
significant (16).
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Given the inconsistency of existing data
on recent nationwide trends in transfusion
following THA, a retrospective cohort
study analyzed the data collected from the
US nationwide inpatient sample (NIS) for
a period of 4 years between 2005 and 2008
and concluded that the incidence of blood
transfusions have recently increased (17%
over the past 4 years) post-operatively fol-
lowing THA with a great variability in
practice (17).
The evidence of ABT reactions led to
the development of blood-saving measures
(BSMs) including preoperative erythro-
poietin (EPO) administration and intra-
and post-operative autologous blood sal-
vage and reinfusion. A study funded by
The Netherlands Organization for Health
Research and Development learned that
physicians experience barriers to using
BSMs due to their techniques, patient
safety, and current blood-management
policies. Physicians participating in the sur-
vey acknowledged using a restrictive trans-
fusion protocol with triggers of hemoglo-
bin threshold as low as 6.4 g/dL. How-
ever, recent trials have proved that BSMs
are not cost-effective (18, 19). The com-
bination of algorithms for blood manage-
ment and restrictive transfusion thresh-
olds contribute to surgeons’ “behavioral
intention,” and whether a surgeon will
tend to “watch and wait” or proceed with
transfusion.
Differences of transfusion preferences
amongst orthopedic surgeons may result
from the necessary balance between man-
aging the consequences of blood loss,
and the risks associated with ABT (20).
Even though it may be essential to sup-
port hemodynamic stability, ABT should
be avoided when possible because of its
associated risks, including increased rates
of infection and LOS (21). A post hoc
analysis of data pulled from the regula-
tion of coagulation in orthopedic surgery
to prevent deep-venous thrombosis and
pulmonary embolism (RECORD) clinical
trial program concluded that the rate of
any infections and wound inflammation
were higher in THA patients receiving ABT
compared to patients receiving autologous
blood transfusion or no transfusion (21,
22). Alteration of host T-cell regulation
and microcirculatory deficits increase the
risk of post-operatory infection. The over-
all infection rate for allogeneic recipients
was documented as 9.7%. By comparison,
patients receiving autologous blood trans-
fusion had a 5.2% infection rate, which is
similar to the rate of infection in patients
not receiving blood at all. Furthermore,
patients receiving ABT had higher rates
of surgical site infection and reoperation
for suspected acute peri-prosthetic infec-
tion (23).
Tranexamic acid (TXA), a synthetic
derivative of the amino-acid lysine has been
used to reduce blood loss and transfusion
requirements in patient undergoing ortho-
pedic surgeries based on its antifibrinolytic
properties. By competitively blocking the
lysine-binding sites on plasminogen, TXA
is able to reduce the local degradation of
fibrin by plasmin (24). Conflicting reports
of increased risks of deep-vein thrombosis
(DVT) in surgical patients receiving TXA
led to a recent meta-analysis performed
to evaluate the safety and efficacy of its
use in major orthopedic surgeries. Encour-
aging data has shown that blood trans-
fusion volumes per patient were signifi-
cantly reduced when TXA was used,and the
rate of DVT was not affected when com-
pared with controls (25). Topical appli-
cation is considered to have less systemic
absorption and better local effect with the
same effectiveness in reducing the blood
transfusion rate as IV-TXA (26). Based
on the effects of the topical form, Huang
et al. published the results of a prospec-
tive study using a combination of IV and
topically administered TXA in orthopedic
surgery [total knee arthroplasties (TKA)].
The study found a better and faster hemo-
static effect in the combined group ver-
sus the IV-TXA group, because of the
higher local concentration of TXA with
a smaller maximum decline of hemoglo-
bin (27).
In 1994, Epoetin alpha was approved
by the Food and Drug Administration
(FDA) for the treatment of anemia asso-
ciated with chronic kidney disease in
order to decrease the need for transfusion.
Since then several studies expressed con-
cern over using erythropoiesis-stimulating
agents (ESAs) to increase hemoglobin con-
centrations. These studies suggest that a
rapid increase in hemoglobin concentra-
tion may trigger hemodynamic instabil-
ity and serious cardiovascular events (28).
Despite the potential concerns, there is
data to suggest that the use of ESAs may
reduce transfusion rates. A meta-analysis
of 26 trials comprising 3,560 patients
undergoing hip or knee arthroplasty was
published in 2013. The study concluded
that ESAs improved post-operative hemo-
globin levels with decreased need for ABT.
It is important to be aware of the safety
concerns associated with ESAs when con-
sidering a more cost-effective, alterna-
tive method to ABT (29). An analysis
of national trends in the utilization of
blood transfusion during total hip and knee
arthroplasty reported a total of 6,056,655
THA and TKAs performed in the US in
the last decade, with an overall transfu-
sion rate of 25.5% for THA and 17.9%
for TKA. The records in the NIS showed
that 16.4% of the THA patients and 17.9%
of TKA patients received an ABT during
surgery. Encouragingly, this data also sup-
ports evidence that the risk of transfusion-
associated HIV and HCV has decreased
dramatically within the last decade. The
study encouraged the creation and utiliza-
tion of a blood-management program by
targeting groups of patients with a higher
risk of blood transfusion in collaboration
with PCP (30). A review of overall blood
usage at a single, academic medical cen-
ter in the Boston area found that ortho-
pedic surgeons were frequently unsuccess-
ful in predicting those who would require
a transfusion. From a group of 62 TKA
patients providing an autologous donation,
only 13 required transfusions. The great
majority of these autologous donations
resulted in wasted resources and expense
with blood draw, storage, and retrieval.
The study concluded that better models
are necessary to predict which patients are
at an increased risk for a blood transfu-
sion during the perioperative period. The
collected data suggest that the preoper-
ative hematocrit is the most important
factor when assessing the need for blood
transfusion, additional variables including
age, race, gender, BMI, and comorbidi-
ties (31).
A retrospective analysis performed at
Duke University Medical Center, North
Carolina analyzed the influence of an
increased BMI on surgeon’s decision to
encourage patients to donate blood pre-
operatively; the“breakthrough”autologous
blood transfusion was reported to decrease
the infection risk when these units are
received prior to any allogeneic transfusion
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requiring more than two units of autolo-
gous blood. The study found that BMI was
not predictive of infection risk (32).
Multiple surveys addressed to Dutch
and UK orthopedic surgeons within the
last decade revealed an increased awareness
and a positive attitude toward perioperative
BSMs. The need for perioperative blood
management directed toward improving
patient outcome with reduced ABT is gen-
erally recognized (31, 33). The hemoglobin
threshold warranting transfusion contin-
ues to be debated among anesthesiologists
and orthopedic surgeons (34).
CONCLUSION
As we continue to study blood-
management strategies associated with
hip surgery, it is important to contrast the
many risk- and benefit-associated blood
transfusions and the use of BSMs. More
recently, the use of antifibrinolytic medica-
tion have been associated with a reduced
intra-operative blood loss and the rate of
post-operative transfusion. This strategy
and others should be investigated further
to establish their safety and effectiveness as
we strive to optimize blood management
during joint arthroplasty.
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